Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study.

08:00 EDT 1st October 2013 | BioPortfolio

Summary of "Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study."

ABSTRACT Objective: The impact of postmenopausal vaginal atrophy and women's coping strategies were evaluated through international focus groups. Methods: Three-hour focus groups of 3-5 postmenopausal women who had symptoms of vaginal atrophy but had not sought treatment were conducted in Canada, Sweden, the United States, and the United Kingdom. Participants were asked about their experience with menopause and vaginal atrophy, including use of nonprescription treatments and their interactions with health care providers. Women were classified as one of 5 personality types, based on their interaction with the world (individualism or belonging) and strategies for coping with stress (control or liberation). Results: Vaginal atrophy was not recognized as a medical condition by focus group participants, and women had not used treatments for vaginal atrophy apart from nonprescription lubricants. Women who had discussed vaginal atrophy symptoms with their doctor felt their concerns were dismissed as a normal part of aging, and they did not receive counseling about treatment options such as low-dose estrogen therapy. Those whose coping strategy involved dominance, combating or individualism were more likely to seek treatment than those whose strategy involved submission, acceptance or belonging. Women who used control to cope with menopausal changes were more likely to respond to information validated by perceived experts than were those who used a strategy of release. Conclusions: Women's reactions to their vaginal atrophy varied according to personality. Use of a personality-based approach to patient counseling may encourage patients to discuss vaginal atrophy with their health care provider and seek treatment.


Journal Details

This article was published in the following journal.

Name: Climacteric : the journal of the International Menopause Society
ISSN: 1473-0804


PubMed Articles [21774 Associated PubMed Articles listed on BioPortfolio]

Attitudes Toward Male and Female Sexuality Among Men and Women with Intellectual Disabilities.

Studies comparing the sexual attitudes of men and women with intellectual disabilities (ID) have been limited. A mixed methods approach was employed to explore attitudes toward sexuality among men and...

Predictors of impact of vaginal symptoms in postmenopausal women.

This study aims to identify factors associated with greater impact of vaginal symptoms on the functioning and well-being of postmenopausal women.

Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations.

Vulvovaginal atrophy is a common condition associated with decreased estrogenization of the vaginal tissue. Symptoms include vaginal dryness, irritation, itching, soreness, burning, dyspareunia, disch...

Vaginal estrogen use and effects on quality of life and urogenital morbidity in postmenopausal women after publication of the Women's Health Initiative in New York City.

In the years after the 2002 publication of results from the Women's Health Initiative study, there has been a reluctance to prescribe hormone therapy to symptomatic postmenopausal women and confusion ...

Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.

This study aims to evaluate the sexual function and quality of life (QoL) of naturally postmenopausal women affected by genitourinary syndrome of menopause who were treated with an ultralow-concentrat...

Clinical Trials [6113 Associated Clinical Trials listed on BioPortfolio]

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.

An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy

Up to 50% of postmenopausal women frequently suffer from atrophic vaginitis or vaginal atrophy with symptoms including vaginal dryness, irritation, burning, itching or discomfort. Vaginal ...

Vaginal Microbiota Among Postmenopausal Women

It is known that vaginal bacteria have an impact upon the health status of the host, in some cases protecting against infection and in other cases causing infection, depending on the bacte...

Study Evaluating Potential Drug Interaction of Bazedoxifene & Premarin in Healthy Postmenopausal Women

Bazedoxifene (BZA) 20 mg tablet is an investigational medication (not approved by FDA) which is being studied for possible prevention and treatment of postmenopausal osteoporosis. PREMARI...

DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy

The purpose of the study is to evaluate the systemic bioavailability of DHEA and its metabolites and the pharmacokinetics of vaginal suppositories at four different DHEA concentration.

Medical and Biotech [MESH] Definitions

An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.

A gonadal stromal neoplasm composed only of THECA CELLS, occurring mostly in the postmenopausal OVARY. It is filled with lipid-containing spindle cells and produces ESTROGENS that can lead to ENDOMETRIAL HYPERPLASIA; UTERINE HEMORRHAGE; or other malignancies in postmenopausal women and sexual precocity in girls. When tumors containing theca cells also contain FIBROBLASTS, they are identified as thecoma-fibroma tumors with less active hormone production.

The procedures through which a group approaches, attacks, and solves a common problem.

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.


Relevant Topics

Latest News Clinical Trials Research Drugs Reports Corporate
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Women's Health
Latest News Clinical Trials Research Drugs Reports Corporate
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Latest News Clinical Trials Research Drugs Reports Corporate
The menopause is a natural event for all women; the ovaries no longer produce estrogen and progesterone. This can be due to natural aging (usual age of onset is 51 years), or through chemotherapy and surgery on the ovaries. The changing balance of the ho...

Searches Linking to this Article